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Recently, therapeutic strategies targeting tumor vasculature have received a great 
×attention in cancer treatment.  Although vascular disrupting agents (VDAs) cause a rapid 
vascular shutdown in solid tumors leading to extensive tumor necrosis as a result of oxygen 
and nutrient deprivation.  However, tumor cells in the tumor periphery survive VDA 
treatment alone.  It is suggested that the tumor cells in the tumor edge are expected to be 
nutritionally supported in part by normal vessels in the surrounding healthy tissue1).  In 
order to kill these surviving cells, VDA treatments are needed to be combined with 
conventional treatment such as radiotherapy or chemotherapy. 
In the previous CYRIC annual report2), we demonstrated that tumor growth delay was 
significantly enhanced in NFSa fibrosarcoma tumors by the combined treatment of proton 
irradiation and the vascular disrupting agent AVE8062 in comparison to proton therapy 
alone or AVE8062 treatment alone, as shown in Fig. 1.  It is expected that the proton 
irradiation may induce therapeutic effects on tumor cells at the tumor periphery which 
survive AVE8062 treatment alone.  In this work, we performed a high-resolution PET 
study using a semiconductor animal PET scanner (Fine-PET)3) and 18F-labeled 
fluorodeoxyglucose (FDG) to evaluate therapeutic effects caused by the combined 
treatment.   
NFSa fibrosarcoma cells (5×106/50µL) were transplanted into both hind legs of 
 62 
C3H/HeSlc male mice aged around 12 weeks old.  When each tumor diameter reached 
about 8 mm, the tumors of the right hind leg were locally irradiated (15 or 30 Gy) using a 
clinical proton beam provided from a horizontal proton irradiation system4) so that the 
tumor volume was covered by the maximum depth dose distribution, the so-called 
spread-out Bragg peak (SOBP).  The size of SOBP was 20 mm in this work.  The tumor 
of the left hind leg was not irradiated.  AVE8062 was administered intraperitonealy to a 
part of the mice receiving 15 Gy at a dose of 40 mg/kg 2 hours after irradiation.  As a 
result, we classified the tumors of the right and left hind legs into proton therapy (15 or 30 
Gy), AVE8062 treatment (40 mg/kg), combined treatment (15 Gy + 40 mg/kg ) and control 
groups. Therapeutic effects caused by each treatment in this work were evaluated 1 day and 
4 days after each single treatment on the basis of glucose uptake inside the tumor.  FDG 
(37 MBq) was administered to the mice from the tail vein.  The FDG-PET scan was 
performed using the Fine-PET scanner from 60 to 120 min after the FDG administration. 
Figure 2 shows results of the FDG-PET measurements.  A significant difference was 
observed in the distribution of FDG uptake between the tumors treated with and without 
AVE8062.  For control and 15-Gy proton therapy groups, FDG uptake was significantly 
high in the whole tumor region on both day 1 and day 4.  On the other hand, FDG 
concentrated only in the tumor periphery on day 1 in the AVE8062 treatment alone and the 
combined treatment due to the shutdown of tumor vasculature.  In addition, FDG 
accumulation in the tumor edge of the combined treatment decreased on day 4 in 
comparison to that of AVE8062 treatment alone.  On the basis of these findings, it is 
expected that AVE8062 may give rise to necrosis in the central region of the tumor and that 
proton irradiation may cause therapeutic effects leading to reduction in FDG uptake on cells 
in the tumor periphery. 
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Figure 1.  Time course of changes in relative tumor volume caused by each single treatment on day 0. 






Figure 2.  High-resolution [18F]FDG-PET images of NFSa tumors 1 or 4 days after each single treatment. 
 
 
 
 
 
 
 
 
